Trevi Therapeutics, Inc. (TRVI) experienced a 5.00% decline in its stock price during Wednesday's intraday session.
The drop followed the announcement that investment firm Morgan Stanley lowered its price target for the company from $19.00 to $18.00, signaling reduced analyst confidence in the stock's near-term valuation prospects.